Literature DB >> 23002981

Vaccination against influenza: role and limitations in pandemic intervention plans.

Terri Rebmann1, Alan Zelicoff.   

Abstract

Influenza pandemics occur periodically and the subtype of the next pandemic strain cannot be predicted. Vaccination remains a critical intervention during pandemics, but current production technology requires several months to develop sufficient vaccine to meet anticipated worldwide need. Candidate prepandemic vaccines for use in population priming or rapid deployment during an epidemic are in development but are subtype specific and logistical obstacles to timely distribution exist. Intensive research is underway to identify a universal vaccine, providing protection against all known influenza strains based on shared epitopes. Vaccine access is expected to be limited during early response to a pandemic, necessitating ethical vaccine distribution plans for within-country and global allocation. Mass vaccination plans must be in place prior to an event to ensure appropriate infrastructures are in place. Carefully crafted education campaigns regarding pandemic vaccine safety and efficacy should aid in maximizing pandemic vaccine uptake during a future event.

Mesh:

Substances:

Year:  2012        PMID: 23002981     DOI: 10.1586/erv.12.63

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  10 in total

1.  A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.

Authors:  Karl-Heinz Herbinger; Frank von Sonnenburg; Hans Dieter Nothdurft; Pamela Perona; Astrid Borkowski; Elena Fragapane; Uwe Nicolay; Ralf Clemens
Journal:  Hum Vaccin Immunother       Date:  2013-09-20       Impact factor: 3.452

2.  Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.

Authors:  Leora R Feldstein; Laura Matrajt; M Elizabeth Halloran; Wendy A Keitel; Ira M Longini
Journal:  Vaccine       Date:  2016-06-20       Impact factor: 3.641

3.  Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.

Authors:  Anne Schuind; Nathan Segall; Mamadou Drame; Bruce L Innis
Journal:  J Infect Dis       Date:  2015-02-25       Impact factor: 5.226

4.  Identification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screening.

Authors:  Nhut Tran; Thanh Van; Hieu Nguyen; Ly Le
Journal:  Int J Med Sci       Date:  2015-01-12       Impact factor: 3.738

5.  Human Vγ9Vδ2-T Cells Synergize CD4+ T Follicular Helper Cells to Produce Influenza Virus-Specific Antibody.

Authors:  Qingyun Chen; Kun Wen; Aizhen Lv; Ming Liu; Ke Ni; Zheng Xiang; Yinping Liu; Wenwei Tu
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

6.  U.S. public support for COVID-19 vaccine donation to low- and middle-income countries during the COVID-19 pandemic.

Authors:  Jeanine P D Guidry; Paul B Perrin; Linnea I Laestadius; Emily K Vraga; Carrie A Miller; Bernard F Fuemmeler; Candace W Burton; Mark Ryan; Kellie E Carlyle
Journal:  Vaccine       Date:  2021-03-09       Impact factor: 3.641

7.  Bioinformatic prediction of epitopes in the Emy162 antigen of Echinococcus multilocularis.

Authors:  Yanhua Li; Xianfei Liu; Yuejie Zhu; Xiaotao Zhou; Chunbao Cao; Xiaoan Hu; Haimei Ma; Hao Wen; Xiumin Ma; Jian-Bing Ding
Journal:  Exp Ther Med       Date:  2013-06-05       Impact factor: 2.447

8.  Identification of Chicken Pulmonary miRNAs Targeting PB1, PB1-F2, and N40 Genes of Highly Pathogenic Avian Influenza Virus H5N1 In Silico.

Authors:  Amod Kumar; Muhasin Asaf Vn; Ashwin Ashok Raut; Richa Sood; Anamika Mishra
Journal:  Bioinform Biol Insights       Date:  2014-06-12

9.  Equalizing access to pandemic influenza vaccines through optimal allocation to public health distribution points.

Authors:  Hsin-Chan Huang; Bismark Singh; David P Morton; Gregory P Johnson; Bruce Clements; Lauren Ancel Meyers
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

10.  CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus.

Authors:  Yujun Pei; Kun Wen; Zheng Xiang; Chunyu Huang; Xiwei Wang; Xiaofeng Mu; Liyan Wen; Yinping Liu; Wenwei Tu
Journal:  Signal Transduct Target Ther       Date:  2020-06-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.